Abstract
Purpose :
Central serous chorioretinopathy (CSC) mainly affects middle-aged men and is characterized by serous detachment of neurosensory retina and retinal pigment epithelium (RPE). Although choroidal neovascularization (CNV) is a well-known complication in eyes with chronic CSC, CNV can also detected in acute CSC, named as neovascular central serous chorioretinopathy（nCSC）. This study is aimed to evaluate neovascular CSC with OCTA.
Methods :
Twenty-three eyes presneting with CSC (35~50 years, 18 male and 5 female) were included in this study. Macular angiograms (3×3 mm) were obtained using spectral-domain OCT (SD-OCT, RTVue XR; Optovue). CNV was defined as flow in the outer retinal slab between the outer plexiform layer and Bruch’s membrane. Eyes with nCSC were treated with anti-VEGF therapy (aflibercept 2.0mg/0.05ml intravitreal injection, 3+PRN). Clinical characteristics and OCTA were performed at the time of no more than two months after diagnosis of CSC and follow-up.
Results :
Of twenty-three eyes with CSC, three eyes (13.04%) with the flat, irregular RPE elevation or PED were determined as type 1 CNV in outer retina of OCTA, even though symptomatic macular detachments resolved spontaneously. All the patients with nCSC were female, who showed a significantly worse initial best corrected visual acuity (BCVA) (Snellen 20/40) compared to eyes with non-neovascular CSC (Snellen 20/25) (p<0.05). BCVA, central macular thickness, subretinal fluid significantly decreased, while the CNV area and vessel density did not change after treatment.
Conclusions :
OCTA provides a promising CNV detection rate in CSC. Eyes with nCSC may have acute CSC, not chronic CSC, and should be carefully examined with OCTA to determine. Anti-VEGF therapy can stabilize the nCSC.
This is a 2021 ARVO Annual Meeting abstract.